Prognostic role of chromogranin A in ：astration-resistant prostate cancer： a meta-analysis
Prognostic role of chromogranin A in ：astration-resistant prostate cancer： a meta-analysis作者机构：Department of UrologyPeking University First Hospital and Institute of UrologyNational Research Centre for Genitourinary OncologyBeijing 100034China.These authors contributed equally to this work.
出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)
年 卷 期：2018年第20卷第6期
页 面：561-566页
核心收录：
学科分类：0710[理学-生物学] 083002[工学-环境工程] 0830[工学-环境科学与工程（可授工学、理学、农学学位）] 07[理学] 08[工学] 09[农学] 0903[农学-农业资源与环境] 071002[理学-动物学] 0713[理学-生态学]
主 题：castration-resistant prostate cancer chromogranin A prognosis
摘 要：We aimed to investigate the prognostic value of chromogranin A （CgA） in castration-resistant prostate cancer （CRPC）. We conducted a systematic literature search of PubMed, Web of Science, and EMBASE for citations published prior to September 2017 that described CgA and CRPC and performed a standard meta-analysis on survival outcomes. Our meta-analysis included eight eligible studies with 686 patients. The results were as follows： progression-free survival （PFS） was associated with CgA level （hazard ratio [HR] = 2.47, 95% confidence interval [CI]： 1.47-4.14, P = 0.0006）; PFS was relative to CgA change （HR = 9.22, 95% Ch 3.03-28.05, P〈 0.0001）; and overall survival （OS） was relative to CgA level （HR = 1.47, 95% Ch 1.15-1.87, P= 0.002）. When we divided the patients into two groups according to therapy status, the result for OS relative to CgA level was an HR of 1.26 （95% CI： 1.09-1.45, P = 0.001） in the first-line hormonal therapy group, and an HR of 2.33 （95% Ch 1.40-3.89, P = 0.001） in the second-line hormonal therapy or chemotherapy group. This meta-analysis indicated that a high CgA level had a negative influence on OS and PFS in CRPC patients. In addition, CRPC patients with a rising CgA had a shorter PFS. Further studies are needed to verify the prognostic value of CgA in CRPC.
维普期刊数据库
